Intetics Is Recognized as Inc. 2023 Power Partner Awards Honoree in the AI & Data Category
October 25, 2023 06:01 ET
|
Intetics Inc.
Inc. named Intetics an honoree on the 2023 Power Partner Awards list in the Artificial Intelligence & Data category.
MarginEdge Recognized by Inc.’s Power Partner Awards and Washington Business Journal’s Fastest Growing Companies 2023
October 24, 2023 08:00 ET
|
MarginEdge
ARLINGTON, Va., Oct. 24, 2023 (GLOBE NEWSWIRE) -- MarginEdge, the leading restaurant management and bill payment platform, today announced it has been recognized by the 2023 Inc. Power Partners...
Text Request Honored with Inc. Power Partner Award for 2nd Year
October 24, 2023 07:33 ET
|
Text Request
CHATTANOOGA, TENN., Oct. 24, 2023 (GLOBE NEWSWIRE) -- Text Request, the industry-leading business messaging platform, has been recognized as an Inc. Power Partner for the second year in a row....
Atea Pharmaceuticals to Present at the Morgan Stanley 21st Annual Global Healthcare Conference
September 06, 2023 07:00 ET
|
Atea Pharmaceuticals, Inc.
BOSTON, Sept. 06, 2023 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral...
Antiviral Combination Therapy Global Market Report 2023
August 24, 2023 12:50 ET
|
ReportLinker
New York, Aug. 24, 2023 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Antiviral Combination Therapy Global Market Report 2023" -...
Barrack, Rodos & Bacine Investigates Napco Security Technologies, Inc. (NSSC)
August 24, 2023 09:30 ET
|
Barrack Rodos & Bacine
PHILADELPHIA, Aug. 24, 2023 (GLOBE NEWSWIRE) -- Barrack, Rodos & Bacine (BR&B) is investigating Napco Security Technologies, Inc. (“Napco”) (NASDAQ: NSSC) for potential violations of federal...
Atea Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Business Update
August 08, 2023 16:05 ET
|
Atea Pharmaceuticals, Inc.
Enrollment continues in global Phase 3 SUNRISE-3 trial evaluating bemnifosbuvir for treatment of COVID-19Phase 3 SUNRISE-3 trial protocol amended to broaden eligibility criteria for high-risk patients...
Atea Pharmaceuticals to Host Second Quarter 2023 Financial Results Conference Call on August 8, 2023
August 01, 2023 07:00 ET
|
Atea Pharmaceuticals, Inc.
BOSTON, Aug. 01, 2023 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral...
Atea Pharmaceuticals Announces First Patient Dosed in Phase 2 Study for Treatment of Hepatitis C with Bemnifosbuvir and Ruzasvir Combination
June 15, 2023 07:00 ET
|
Atea Pharmaceuticals, Inc.
BOSTON, June 15, 2023 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral...
Atea Pharmaceuticals to Present at the Jefferies Healthcare Conference
June 05, 2023 16:20 ET
|
Atea Pharmaceuticals, Inc.
BOSTON, June 05, 2023 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral...